Form 4: AIM ImmunoTech Director Reorganizes Share Holdings Under 10b5-1 Plan

AIM ImmunoTech Director and 10% Owner Ted D. Kellner has filed a Form 4 disclosing a planned transfer of his directly held shares to Kelvest I LP, effective July 17, 2025, under a Rule 10b5-1 plan.

Summary

• Ted D. Kellner, a Director and 10% Owner of AIM ImmunoTech Inc. (AIM), filed a Form 4 disclosing changes in his beneficial ownership.
• The filing indicates a transaction made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.
• The earliest transaction date reported is July 17, 2025.
• Mr. Kellner transferred all of his directly beneficially owned shares to Kelvest I LP.
• Following this transaction, Mr. Kellner's beneficial ownership of AIM Common Stock is entirely indirect, totaling 37,205 shares.
• This indirect ownership includes 34,255 shares held by Kelvest I LP, 2,700 shares by Beta Fund Investment Club, and 250 shares by the Kellner, Ted Combined Profit Sharing/Money Purchase Plan.
• Mr. Kellner serves as Manager of T&M Partners LLC, the General Partner of Kelvest I LP, and as manager and investor for Beta Fund Investment Club (disclaiming beneficial ownership except for pecuniary interest), and as trustee for his Profit Sharing/Money Purchase Plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing reports a re-organization of beneficial ownership by a director and 10% owner, not a sale or purchase of shares. The use of a Rule 10b5-1 plan indicates a pre-planned and transparent action.

Positives

• The transfer of shares to Kelvest I LP, an entity controlled by Mr. Kellner, suggests a strategic consolidation of his holdings, potentially for estate planning or investment management purposes, without divesting his interest in the company.
• The use of a Rule 10b5-1 plan indicates a pre-planned and transparent approach to managing equity holdings.

Risks

• The indirect nature of ownership through various entities (Kelvest I LP, Beta Fund Investment Club, Profit Sharing/Money Purchase Plan) could introduce complexity in tracking ultimate beneficial ownership, although Mr. Kellner maintains control or influence over these entities.
• While a 10b5-1 plan provides an affirmative defense against insider trading allegations, the future transaction date (July 17, 2025) means the actual transfer has not yet occurred as of the filing date (July 21, 2025), which is standard for 10b5-1 disclosures.

Future Outlook

NA

Management Comments

• The reporting person transferred all of his shares owned beneficially to Kelvest I LP. The shares listed here include these shares.
• Shares held by Kelvest I LP, for which the reporting person serves as Manager of T&M Partners LLC, General Partner of Kelvest I LP.
• Shares held by the Beta Fund Investment Club, for which the reporting person serves as the manager and is an investor. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
• Shares held by the Kellner, Ted Combined Profit Sharing/Money Purchase Plan, for which the reporting person serves as trustee.

Industry Context

This filing is specific to an individual insider's shareholding structure and does not directly relate to broader industry trends or competitors, beyond the general context of corporate governance and insider transparency in publicly traded companies.

Corporate Governance

Related Party Transactions

• The transfer of shares from Ted D. Kellner to Kelvest I LP can be considered a related party transaction, as Mr. Kellner serves as Manager of T&M Partners LLC, the General Partner of Kelvest I LP, thereby maintaining control over the transferred shares.

Stakeholder Impact

• Shareholders: The re-organization of a significant insider's holdings provides transparency regarding the structure of their ownership, but does not represent a divestment or acquisition of shares in the open market.
• Management: No direct impact on company management or operations.

Next Steps

• The actual transfer of shares to Kelvest I LP is expected to occur on July 17, 2025, as per the Rule 10b5-1 plan.

Key Dates

Keywords

AIM ImmunoTech, Ted D. Kellner, Form 4, Insider Trading, Beneficial Ownership, Rule 10b5-1, Equity Transfer, Director Holdings, AIM